MSH6 and familial pancreatic carcinoma: From a set of 147 pancreatic cancer cases undergoing an in-house custom 59-gene panel, 6 pathogenic variants were identified in ATM, BRCA1, BRCA2, MRE11A, and PALB2, and 6 HiP-VUS in ATM, BRCA2, CHEK2, MSH6, and TP53. In addition to in silico predictions, CHEK2 p.(T476 M) was found to be damaging in a functional assay for CHEK2 variants, and was thus weighted more strongly towards being pathogenic [42].